Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.39
IPXL's Cash to Debt is ranked higher than
55% of the 1176 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. IPXL: 0.39 )
IPXL' s 10-Year Cash to Debt Range
Min: 0.39   Max: No Debt
Current: 0.39

Equity to Asset 0.50
IPXL's Equity to Asset is ranked higher than
61% of the 978 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IPXL: 0.50 )
IPXL' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.84
Current: 0.5

0.2
0.84
Interest Coverage 2065.49
IPXL's Interest Coverage is ranked higher than
71% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. IPXL: 2065.49 )
IPXL' s 10-Year Interest Coverage Range
Min: 1.51   Max: 9999.99
Current: 2065.49

1.51
9999.99
F-Score: 7
Z-Score: 3.38
M-Score: -1.75
WACC vs ROIC
11.49%
7.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.88
IPXL's Operating margin (%) is ranked higher than
79% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. IPXL: 11.88 )
IPXL' s 10-Year Operating margin (%) Range
Min: -1418.74   Max: 44.72
Current: 11.88

-1418.74
44.72
Net-margin (%) 7.19
IPXL's Net-margin (%) is ranked higher than
74% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. IPXL: 7.19 )
IPXL' s 10-Year Net-margin (%) Range
Min: -1376.35   Max: 46
Current: 7.19

-1376.35
46
ROE (%) 5.11
IPXL's ROE (%) is ranked higher than
69% of the 1163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. IPXL: 5.11 )
IPXL' s 10-Year ROE (%) Range
Min: -341.31   Max: 125.75
Current: 5.11

-341.31
125.75
ROA (%) 3.72
IPXL's ROA (%) is ranked higher than
73% of the 1187 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. IPXL: 3.72 )
IPXL' s 10-Year ROA (%) Range
Min: -70.9   Max: 38.8
Current: 3.72

-70.9
38.8
ROC (Joel Greenblatt) (%) 20.84
IPXL's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1182 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. IPXL: 20.84 )
IPXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.18   Max: 235.82
Current: 20.84

-297.18
235.82
Revenue Growth (3Y)(%) 3.50
IPXL's Revenue Growth (3Y)(%) is ranked higher than
68% of the 974 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. IPXL: 3.50 )
IPXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 203.4
Current: 3.5

0
203.4
EBITDA Growth (3Y)(%) 1.60
IPXL's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IPXL: 1.60 )
IPXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 61.6
Current: 1.6

0
61.6
EPS Growth (3Y)(%) -5.80
IPXL's EPS Growth (3Y)(%) is ranked higher than
67% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. IPXL: -5.80 )
IPXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.2   Max: 55.1
Current: -5.8

-32.2
55.1
» IPXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

IPXL Guru Trades in Q2 2014

NWQ Managers 984,841 sh (New)
John Hussman 310,000 sh (+40.91%)
Paul Tudor Jones 18,000 sh (unchged)
Jim Simons Sold Out
RS Investment Management 940,950 sh (-29.17%)
» More
Q3 2014

IPXL Guru Trades in Q3 2014

Jim Simons 39,400 sh (New)
Joel Greenblatt 33,709 sh (New)
Paul Tudor Jones 36,853 sh (+104.74%)
NWQ Managers 1,298,995 sh (+31.90%)
RS Investment Management 809,959 sh (-13.92%)
John Hussman 250,000 sh (-19.35%)
» More
Q4 2014

IPXL Guru Trades in Q4 2014

Alan Fournier 533,100 sh (New)
Mario Gabelli 6,775 sh (New)
Joel Greenblatt 79,609 sh (+136.17%)
Jim Simons 61,400 sh (+55.84%)
Paul Tudor Jones 39,050 sh (+5.96%)
John Hussman 250,000 sh (unchged)
RS Investment Management Sold Out
NWQ Managers 906,043 sh (-30.25%)
» More
Q1 2015

IPXL Guru Trades in Q1 2015

George Soros 61,206 sh (New)
Alan Fournier 2,025,000 sh (+279.85%)
Jim Simons 71,900 sh (+17.10%)
NWQ Managers 936,127 sh (+3.32%)
John Hussman 250,000 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli Sold Out
Paul Tudor Jones 9,300 sh (-76.18%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 73.10
IPXL's P/E(ttm) is ranked higher than
71% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.50 vs. IPXL: 73.10 )
IPXL' s 10-Year P/E(ttm) Range
Min: 4.04   Max: 1043
Current: 73.1

4.04
1043
Forward P/E 20.70
IPXL's Forward P/E is ranked higher than
88% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IPXL: 20.70 )
N/A
PE(NRI) 73.10
IPXL's PE(NRI) is ranked higher than
72% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 59.20 vs. IPXL: 73.10 )
IPXL' s 10-Year PE(NRI) Range
Min: 4.04   Max: 1043
Current: 73.1

4.04
1043
P/B 3.70
IPXL's P/B is ranked higher than
69% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.15 vs. IPXL: 3.70 )
IPXL' s 10-Year P/B Range
Min: 1.32   Max: 14.47
Current: 3.7

1.32
14.47
P/S 5.24
IPXL's P/S is ranked higher than
55% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.31 vs. IPXL: 5.24 )
IPXL' s 10-Year P/S Range
Min: 1.17   Max: 12.72
Current: 5.24

1.17
12.72
PFCF 85.57
IPXL's PFCF is ranked higher than
77% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 662.20 vs. IPXL: 85.57 )
IPXL' s 10-Year PFCF Range
Min: 1.96   Max: 302
Current: 85.57

1.96
302
POCF 44.01
IPXL's POCF is ranked higher than
76% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.64 vs. IPXL: 44.01 )
IPXL' s 10-Year POCF Range
Min: 1.75   Max: 2002
Current: 44.01

1.75
2002
EV-to-EBIT 48.38
IPXL's EV-to-EBIT is ranked higher than
73% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.19 vs. IPXL: 48.38 )
IPXL' s 10-Year EV-to-EBIT Range
Min: -642.3   Max: 628.6
Current: 48.38

-642.3
628.6
Shiller P/E 28.95
IPXL's Shiller P/E is ranked higher than
88% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IPXL: 28.95 )
IPXL' s 10-Year Shiller P/E Range
Min: 10.23   Max: 61.99
Current: 28.95

10.23
61.99
Current Ratio 2.44
IPXL's Current Ratio is ranked higher than
73% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. IPXL: 2.44 )
IPXL' s 10-Year Current Ratio Range
Min: 1.12   Max: 10.65
Current: 2.44

1.12
10.65
Quick Ratio 1.95
IPXL's Quick Ratio is ranked higher than
75% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. IPXL: 1.95 )
IPXL' s 10-Year Quick Ratio Range
Min: 0.63   Max: 10.07
Current: 1.95

0.63
10.07
Days Inventory 107.01
IPXL's Days Inventory is ranked higher than
78% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 145.57 vs. IPXL: 107.01 )
IPXL' s 10-Year Days Inventory Range
Min: 50.25   Max: 398.94
Current: 107.01

50.25
398.94
Days Sales Outstanding 106.08
IPXL's Days Sales Outstanding is ranked higher than
67% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 91.38 vs. IPXL: 106.08 )
IPXL' s 10-Year Days Sales Outstanding Range
Min: 34.05   Max: 1169.47
Current: 106.08

34.05
1169.47

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.92
IPXL's Price/DCF (Projected) is ranked higher than
84% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IPXL: 2.92 )
IPXL' s 10-Year Price/DCF (Projected) Range
Min: 0.94   Max: 3.82
Current: 2.92

0.94
3.82
Price/Median PS Value 1.67
IPXL's Price/Median PS Value is ranked higher than
64% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. IPXL: 1.67 )
IPXL' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 26.88
Current: 1.67

0.42
26.88
Earnings Yield (Greenblatt) 2.10
IPXL's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. IPXL: 2.10 )
IPXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 55.9
Current: 2.1

0.2
55.9
Forward Rate of Return (Yacktman) -24.44
IPXL's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.53 vs. IPXL: -24.44 )
IPXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.6   Max: 144.8
Current: -24.44

-24.6
144.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:ILR.Germany,
Impax Laboratories Inc is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Company develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product develop
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
comment on IPXL Sep 24 2012 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 

More From Other Websites
IMPAX LABORATORIES INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders May 22 2015
IMPAX LABORATORIES INC Financials May 20 2015
IMPAX LABORATORIES INC Files SEC form 8-K/A, Financial Statements and Exhibits May 15 2015
Top New Picks of Healthcare Fund Blue Jay Capital: Endo International plc (ENDP), Alkermes Plc... May 14 2015
Impax to Present at the UBS 2015 Global Healthcare Conference May 14 2015
Impax to Present at the UBS 2015 Global Healthcare Conference May 14 2015
10-Q for Impax Laboratories, Inc. May 13 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 13 2015
5 New Biotech Developments Worth Watching May 13 2015
Impax Q1 Earnings Miss Expectations, Revenues Surge Y/Y - Analyst Blog May 12 2015
Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers May 11 2015
Impax Labs reports 1Q loss May 11 2015
Impax Labs reports 1Q loss May 11 2015
FDA Performs GMP and Pre-Approval Inspections of Impax's Hayward Facility May 11 2015
Impax Reports First Quarter 2015 Financial Results May 11 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 11 2015
FDA Performs GMP and Pre-Approval Inspections of Impax's Hayward Facility May 11 2015
Impax Reports First Quarter 2015 Financial Results May 11 2015
Q1 2015 Impax Laboratories Inc Earnings Release - After Market Close May 11 2015
Will BioDelivery Sciences (BDSI) Miss this Earnings Season? - Analyst Blog May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK